(44.192.15.251)
[ij] [ij] [ij] 
Email id
 

Research Journal of Pharmacy and Technology
Year : 2019, Volume : 12, Issue : 6
First page : ( 2999) Last page : ( 3006)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2019.00507.9

Development of New Src Inhibitors

Alnukari Samar1,*, Sliman Faten2

1Master Student in Pharmaceutics and Pharmaceutical Technology Department Faculty of Pharmacy, Tishreen University, Syria

2Doctor in Pharmaceutical Chemistry Department Faculty of Pharmacy, Tartous University, Syria, Fatensliman@tartous-univ.edu.sy

*Corresponding Author E-mail: nukkarisamar@gmail.com

Online published on 8 August, 2019.

Abstract

Protein kinase, especially tyrosine kinase Src, is considered as an important target for cancer therapy such as lung, prostate and central nervous system cancers, as well as its involvement in tumor metastasis. The aim of this study was to find effective and selective inhibitors of Src protein kinase using molecular modeling study, a library of chemical compounds derived from purine and Theophylline cores was then docked within the active site of the Src enzyme. The link affinity and the attitudes of binding of the suggested compounds with the active site of the previously prepared Src enzyme were determined of these compounds. The study led to three effective and highly selective compounds on the Src enzyme; two compounds derived from the Purine core Pur46 and Pur49 and one compound derived from Theophylline core Theo21. The study was completed by chemical synthesis of Theo23 molecule.

Top

Keywords

Tyrosine Kinase, Molecular Modeling, Docking, Src, Cancer.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
720,388,680 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.